Lung cancer: A new generation of EGFR inhibition

Nature Reviews Clinical Oncology

Volumn 12, Issue 7, 2015, Pages 373-

  Killock, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MERELETINIB; ROCILETINIB; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; MAXIMUM TOLERATED DOSE; NON SMALL CELL LUNG CANCER; NOTE; OVERALL SURVIVAL; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; FEMALE; GENETICS; LUNG NEOPLASMS; MALE;

ACRYLAMIDES; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84933278781     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.93     Document Type: Note

References (2)

1. Jänne P. A., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372, 1689-1699 (2015
2. Sequist L. V., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1700-1709 (2015